Evidence map›Paper›PMID 39773053›Full record

ArticleCurrent pharmaceutical biotechnology2025

Strengthening Effect of Thalidomide Combined with an Anti-PD1 Antibody on Enhancing Immunity for Lung Cancer Therapy.

Qing Liu, Zu-Chian Chiang, Xiangqian Zhao, Dongya Cui, Xinxin Li, Hao Chen, Fangyu Lin, Tao Jiang, Qi Chen, Xiaoyan Lin and 1 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Current pharmaceutical biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07671534 (GEMINI), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07671534 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

GEMINI: Phase II Study Using Metronomic Gemcitabine, Mitomycin C, and Thalidomide for Advanced Solid Tumors

TypeinterventionalSponsorSarcoma Oncology Research Center, LLCRan2026 to 2029Enrolled60ConditionsSolid Tumor CancerArmsGemcitabine, Mitomycin C, Thalidomide
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qing LiuThe Oncology Department of Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Zu-Chian ChiangFujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, Fujian, China.
Xiangqian ZhaoFujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, Fujian, China.
Dongya CuiFujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, Fujian, China.
Xinxin LiThe Cancer Center, Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Hao ChenThe Oncology Department of Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Fangyu LinThe Oncology Department of Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Tao JiangThe Oncology Department of Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Qi ChenFujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Fujian Normal University, Fuzhou, Fujian, China.
Xiaoyan LinThe Oncology Department of Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.
Jizhen LinThe Cancer Center, Union Hospital, Fujian Medical University, Fuzhou, Fujian, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesCombining immune checkpoint inhibitors and antiangiogenic agents offers a promising strategy to counteract the cooperative promotion of solid tumor growth by immune checkpoints and intratumoral angiogenesis.

methodsWe investigated the potential of thalidomide (THD) and anti-PD-1 antibody (PD-1 mAb) in suppressing tumor growth, enhancing immunity, and inhibiting angiogenesis.

resultsTHD exhibited regulatory effects on PD-1 in CD4

conclusionThis study highlights THD's role in modifying the tumor microenvironment to enhance PD-1 mAb efficacy, proposing a clinically feasible approach for improving PD-1 mAb treatment outcomes.

Indexed as

Antibodies, MonoclonalImmune Checkpoint InhibitorsLung NeoplasmsProgrammed Cell Death 1 ReceptorThalidomideA549 CellsAngiogenesis InhibitorsAnimalsCarcinoma, Lewis LungCD4-Positive T-LymphocytesCell Line, TumorHumansMiceMice, Inbred C57BLNeovascularization, PathologicTumor MicroenvironmentAngiogenesis InhibitorsAntibodies, MonoclonalImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 ReceptorThalidomideImmune checkpoint inhibitorPD-1 mAbperipheral blood mononuclear cellssuppressing neovascularizationthalidomidetumors.

Identifiers

PMID39773053

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.